Emanual Maverakis, MD
Dermatology · Sacramento, CANPI 1942274592
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,384 of the $61,100 with a category attached, or 77.6%. 21 manufacturers reported payments, led by AbbVie at 50.7% of the total. Among dermatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $430.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$31K
- Argenx US, Inc.$10K
- Sanofi$4K
- Kyowa Kirin Co., Ltd$4K
- E.r. Squibb & Sons, L.L.C.$4K
- F. Hoffmann-la Roche AG$2K
- plus $6K from 15 others
Across 395 payments — averaging $8718.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.8M
- Eli Lilly$674K
- Novartis$321K
- Amgen$205K
- Hoffmann-la Roche Limited$164K
- Sanofi US Services Inc.$109K
- plus $129K from 5 others
What the payments were for
- Consulting fees$47,38478%
- Speaking & faculty fees$2,1133%
- Travel & lodging$5,5269%
- Food & beverage$6,06310%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $30,989 |
| Argenx US, Inc. | 10 | $9,762 |
| Sanofi | 15 | $4,322 |
| Kyowa Kirin Co., Ltd | 7 | $4,157 |
| E.r. Squibb & Sons, L.L.C. | 22 | $3,723 |
| F. Hoffmann-la Roche AG | 3 | $2,113 |
| LEO Pharma AS | 1 | $1,810 |
| Pfizer | 5 | $1,244 |
| Novartis | 16 | $1,127 |
| Galderma Laboratories, L.p. | 5 | $423 |
| Sun Pharmaceutical Industries Inc. | 9 | $318 |
| LEO Pharma Inc. | 3 | $278 |
| Amgen | 4 | $271 |
| Regeneron | 5 | $247 |
| Regeneron Healthcare Solutions, Inc. | 1 | $111 |
| Eli Lilly | 1 | $60 |
| Incyte Corporation | 1 | $48 |
| Janssen Scientific Affairs, LLC | 2 | $46 |
| Tactile Systems Technology Inc | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,100 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 182 | $699,611 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 23 | $469,438 |
| Humira(Cf) PenAdalimumab | 43 | $421,459 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $307,148 |
| XolairOmalizumab | 58 | $295,413 |
| Skyrizi PenRisankizumab-Rzaa | 15 | $293,948 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $276,602 |
| SkyriziRisankizumab-Rzaa | 13 | $234,339 |
| Taltz AutoinjectorIxekizumab | 21 | $187,666 |
| Dupixent SyringeDupilumab | 45 | $178,476 |
| StelaraUstekinumab | 12 | $167,290 |
| RinvoqUpadacitinib | 21 | $128,017 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $116,558 |
| Epinephrine | 14 | $3,302 |
| Clobetasol Propionate | 58 | $2,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi, Rinvoq | $30,989 | $362,35634 claims |
| PfizerOctagam | $1,244 | $276,60213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,875 dermatology providers in California.
Other dermatology in Sacramento
- Raja SivamaniSacramento$1.9M
- Emil TanghettiSacramento$800K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Tien NguyenFountain Valley$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.